As of 2024-12-13, the EV/EBITDA ratio of Cytosorbents Corp (CTSO) is -2.90. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CTSO's latest enterprise value is 56.84 mil USD. CTSO's TTM EBITDA according to its financial statements is -19.60 mil USD. Dividing these 2 quantities gives us the above CTSO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 19.6x - 22.0x | 21.2x |
| Forward P/E multiples | 21.3x - 22.9x | 21.8x |
| Fair Price | (7.79) - (8.03) | (7.86) |
| Upside | -974.3% - -1001.6% | -982.5% |
| Date | EV/EBITDA |
| 2024-12-11 | -2.87 |
| 2024-12-10 | -2.85 |
| 2024-12-09 | -2.87 |
| 2024-12-06 | -2.96 |
| 2024-12-05 | -3.00 |
| 2024-12-04 | -3.11 |
| 2024-12-03 | -3.06 |
| 2024-12-02 | -3.20 |
| 2024-11-29 | -3.12 |
| 2024-11-27 | -2.95 |
| 2024-11-26 | -2.92 |
| 2024-11-25 | -3.01 |
| 2024-11-22 | -2.98 |
| 2024-11-21 | -2.90 |
| 2024-11-20 | -2.97 |
| 2024-11-19 | -3.09 |
| 2024-11-18 | -3.01 |
| 2024-11-15 | -2.91 |
| 2024-11-14 | -3.06 |
| 2024-11-13 | -3.00 |
| 2024-11-12 | -3.12 |
| 2024-11-11 | -3.01 |
| 2024-11-08 | -2.48 |
| 2024-11-07 | -2.93 |
| 2024-11-06 | -2.98 |
| 2024-11-05 | -2.82 |
| 2024-11-04 | -2.84 |
| 2024-11-01 | -3.20 |
| 2024-10-31 | -3.23 |
| 2024-10-30 | -3.23 |
| 2024-10-29 | -3.26 |
| 2024-10-28 | -3.23 |
| 2024-10-25 | -3.32 |
| 2024-10-24 | -3.34 |
| 2024-10-23 | -3.34 |
| 2024-10-22 | -3.32 |
| 2024-10-21 | -3.34 |
| 2024-10-18 | -3.46 |
| 2024-10-17 | -3.57 |
| 2024-10-16 | -3.54 |
| 2024-10-15 | -3.46 |
| 2024-10-14 | -3.48 |
| 2024-10-11 | -3.54 |
| 2024-10-10 | -3.34 |
| 2024-10-09 | -3.57 |
| 2024-10-08 | -3.57 |
| 2024-10-07 | -3.57 |
| 2024-10-04 | -3.73 |
| 2024-10-03 | -3.85 |
| 2024-10-02 | -4.15 |